WILSONHCG ACQUIRES PERSONIFY FOR HEALTHCARE, LIFE SCIENCES TALENT SOLUTIONS EXPANSIONS

KUALA LUMPUR, Jan 11 (Bernama) — WilsonHCG, a global talent leader, has acquired Personify, a recruitment process outsourcing (RPO) provider to further expand its healthcare and life sciences talent solutions.

Headquartered in Raleigh, North Carolina, United States, Personify specialises in the life sciences, healthcare, biotechnology and pharmaceuticals sectors and other industries experiencing critical skills shortages, providing executive search and recruitment marketing services alongside its RPO solutions.

“This expansion enables continued growth while cementing our position as a global leader in talent acquisition.

“The partnership aligns two mission-driven organisations with a desire to exceed client expectations and together, we’ll set new standards in the talent space,” said WilsonHCG chief executive officer (CEO), John Wilson in a statement.

Meanwhile, Personify president and CEO, Ryan Carfley said: “The partnership accelerates our access to new markets, and together we’ll become the global go-to talent solutions provider in healthcare, biotechnology, life sciences and beyond.”

WilsonHCG completed two acquisitions last year in which the company acquired Tracking Talent, a talent solutions provider based in South Africa, in October and in March, it acquired Claro Analytics, a leading labour market intelligence platform.

— BERNAMA

FURA GEMS SPARKLES, INITIATING CERTIFICATION WITH RESPONSIBLE JEWELLERY COUNCIL

KUALA LUMPUR, Jan 11 (Bernama) — FURA Gems Inc, a coloured gemstone mining and marketing company has initiated the certification process with the Responsible Jewellery Council (RJC), demonstrating its commitment to responsible business practices.

In a statement, it said the project will be headed by Mazars Switzerland, which will accompany FURA Gems and all its operating mining locations in Colombia for emeralds, Mozambique for rubies, and Australia for sapphire through the process of RJC preparation.

FURA has already registered its Australian location with RJC, and will now look to expand the certification for the group and all its operating sites.

With Mazar’s support, FURA will target to complete the certification process on or before Dec 31, this year for all its operating locations.

FURA Gems founder and chief executive officer, Dev Shetty said: “This is a strong statement from our side, as we launch certification of all our mines producing emeralds, rubies and sapphires.

“The certification process will enable us to formalise our commitment since our foundation is to provide the jewellery market with traceable, sustainably sourced colour gemstones.

“To achieve this, we have identified Mazars as the ideal partner to conduct the process throughout our production sites and at the headquarters level,” added Shetty.

Meanwhile, partner at Mazars, Franck Paucod said: “With our experiences in the gems and jewellery sector, we will be able to support FURA with its commitment to building the solid framework to achieve the RJC certification.”

The certification with RJC is part of the ambitious environmental, social and governance (ESG) strategy deployed by FURA since its foundation in 2017.

— BERNAMA

CONAGEN STARTS FIRST COMMERCIAL PRODUCTION OF SUSTAINABLE TYRIAN PURPLE FOR TEXTILE DYE

New era for green tech alternatives to replace petrochemical synthesized dyes.

Bedford, Mass., Jan 10 (Bernama-GLOBE NEWSWIRE) — Conagen announced the successful scale-up of its sustainable, cost-effective Tyrian purple, a historically coveted and expensive dye found in rare and limited sources in marine nature.

Conagen is the world’s first and only biotechnology company commercializing a sustainable Tyrian purple by fermentation. As with any biologically-sourced textile dye, this color-fast compound reduces pollution and carbon footprints when used as an alternative to petrochemically synthesized dyes commonly used in the textiles industry today.

Also known as Phoenician purple, royal purple, imperial purple, or imperial dye, this rare dye dates back several millennia to the bronze age when the Phoenicians from Tyre, Lebanon, on the Levantine coast, produced it for the ancient Greeks, Persians, Byzantines, and the Roman empire to clad emperors and kings with luxury textiles. Tyrian purple was once worth more than its weight in gold for its prized deep rich purple. In 301 CE, during the Roman Empire, one pound of Tyrian purple dye was priced at approximately three Troy pounds of gold, roughly $66,000 in today’s currency.

Current producers extract and harvest Tyrian purple from the murex shellfish in much the same way as the ancient Phoenicians. Thousands — approximately 10,000 or (54 kilograms (119 lb.) of these predatory sea snails are required to make diminishing quantities of Tyrian purple to produce 1 gram of the dye, making it impracticable, expensive, and environmentally unfriendly. Ancient dye producers all but drove the murex species to extinction along the coasts of Phoenicia, evident in the vast deposits of the shells excavated on the outskirts of Sidon, Tyre, and across the Mediterranean.

Conagen’s Tyrian purple, produced by precision fermentation and bioconversion, is a natural, sustainable dye ideal for textile companies under pressure to deliver fashions more sustainably and with a reduced global environmental footprint, especially from manufacturing.

“Conagen is democratizing the exclusive use of a color once reserved for royalty — now obtainable on a global scale,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “Our fermentation and bioconversion technologies enable us to offer true-to-nature products. By leveraging Conagen’s bioengineering and commercial manufacturing capabilities, we’re unlocking Tyrian purple’s great potential as an accessible and sustainable dye. We expect Tyrian purple to inspire fresh ideas in multiple industries, making this rare and exciting color more marketable with planet-conscious consumers.”

The Tyrian purple technology is based on two of Conagen’s many key bioengineering platforms, which enable accelerated product development timelines for its competitive phenolics, terpenoids, proteins, and peptide molecules.

As an example, Conagen’s phenolics platform was used to make an important antioxidant, hydroxytyrosol, the active health ingredient found in oil, juice, and fruit in olives. Using another platform, Conagen has optimized the production of different amino acid-based products, including the nutraceutical antioxidant ergothioneine, a “longevity vitamin” currently branded as “Ergoactive” by Conagen’s pipeline partner Blue California. To produce the Tyrian purple, Conagen drew from both proprietary platforms to develop novel enzymes which increase the conversion efficiency of precursors to the dye.

“Conagen has further solidified its leadership in the bioeconomy by rapidly producing multiple novel and interesting molecules, such as Tyrian purple,” said Lippmeier. “Our technology platforms have been meticulously engineered and improved upon for over a decade, and they are extremely efficient at making targeted compounds from an expanding array of molecular classes for our internal product development and collaborative ventures.”

Conagen aims to replace petroleum-based ingredients and reduce carbon footprints with green technologies. Tyrian purple adds to Conagen’s natural color offerings, including several carotenoids made by fermentation which have been scaled to global production. As a dye, Tyrian purple is ideal for textile fabrics, clothing, handbags, and related accessories.

###

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use modern synthetic biology tools to program micro-organisms and enzymes on a molecular level to produce high-quality, sustainable, natural products manufactured worldwide via precision fermentation and bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceuticals, and renewable materials.

Attachments



Ana Arakelian, Head of Public Relations and Communications
Conagen
+1-781-271-1588
ana.arakelian@conagen.com

SOURCE : Conagen

BC PLATFORMS SELECTED TO DELIVER KEY SINGAPORE POPULATION HEALTH STUDY

KUALA LUMPUR, Jan 9 (Bernama) — BC Platforms (BCP), a global leader in healthcare data management and analytics, has been selected to analyse and manage data collected from the Health for Life in Singapore (HELIOS) study, which forms part of the SG100K data set for Singapore’s National Precision Medicine programme.

The HELIOS study is a state-of-the-art population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore).

According to BCP in a statement, the population study aims to identify environmental, lifestyle and genetic factors that cause heart disease, diabetes, cancer, and other chronic diseases in Singapore.

“I’m delighted that we have more good news coming out of Singapore, a major focus for deploying our clinical solutions and driving precision medicine, where we are working with leading Asian healthcare institutions.

“This latest partnership should make it easier for health service providers to determine optimal patients treatment pathways in major diseases areas, based on population health insights using our genomic data management platform,” said its deputy managing director, Nino da Silva.

As part of Singapore’s SG100K study, the HELIOS study will recruit up to 50,000 men and women, aged 30-84 years old, from the Singapore population progressively over the next two years.

BCP will be providing BC|INSIGHT and BC|RQUEST for management of LKCMedicine’s genotype and phenotype patient data from a large Asian cohort in a safe and secure manner.

The project will benefit from BCP’s latest software solution, the ‘Trusted Collaboration Environment’ and the recently upgraded to its acclaimed BC|INSIGHT open platform version 7.

The platform has a high focus on user experience, it is fully equipped with cohort building tools and capabilities to automate data release approval processes and highly dynamic open workspaces.

— BERNAMA

TESSA THERAPEUTICS UNVEILS 2023 STRATEGIC OUTLOOK, CORPORATE UPDATE

KUALA LUMPUR, Jan 4 (Bernama) — Singapore-based Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumours, will prioritise the development of its allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy platform this year.

At the same time, the company will seek strategic options for the development of its TT11 autologous CAR-T platform with other companies, based on its strategic outlook and corporate update for 2023.

“The decision to prioritise the allogeneic or “off-the-shelf-approach” over the autologous platform followed the progress and new data with the TT11X clinical programme.

“The data demonstrated TT11X to be well-tolerated at all dosing levels, eliciting a 79 per cent overall response rate and 43 per cent complete response rate among 14 heavily pre-treated CD30-positive Hodgkin lymphoma patients,” it said in a statement today.

The company added that these developments are the first of what is expected to be a milestone-rich year ahead as the company seeks to build the value of its pipeline to its fullest potential with available resources.

Its president and chief executive officer (CEO), Thomas Willemsen said he believed that this strategic refocus on the allogeneic platform positions the company at the forefront of CAR-T innovation for 2023 and beyond.

“This optimism is based on the compelling safety and efficacy data that continue to be generated by our TT11X programme and the potential patient benefit in treating CD30-positive lymphomas, and potentially solid tumours where there is a significant unmet medical need,” he said.

In 2022, Tessa enhanced its executive management team with the appointment of Willemsen as CEO and Wilson W. Cheung as chief financial officer.

The company also expanded its board with the addition of Amy Schulman and Darren Carroll from Polaris Partners, which led the company’s US$126 million Series A financing round.

— BERNAMA